Rethinking mechanisms of autoimmune pathogenesis

Journal of Autoimmunity

Volumn 45, Issue , 2013, Pages 97-103

  Pillai, Shiv ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autoimmunity; Epigenetics; Genetic variants; Microbiome; SIAE

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ESTERASE; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PROGRAMMED DEATH 1 LIGAND 1; SIALIC ACID ACETYL ESTERASE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLELE; ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BORRELIA BURGDORFERI; CROHN DISEASE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE FLORA; MULTIPLE SCLEROSIS; MYCOBACTERIUM TUBERCULOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ULCERATIVE COLITIS;

AUTOIMMUNITY; EPIGENETICS; GENETIC VARIANTS; MICROBIOME; SIAE;

ACETYLESTERASE; ANIMALS; AUTOIMMUNE DISEASES; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; INTESTINES; MICROBIOTA; POLYMORPHISM, GENETIC; TH1-TH2 BALANCE;

EID: 84884352609     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.05.003     Document Type: Review

References (82)

1. Burnet F.M., Fenner F. The production of antibodies 1949, Macmillan and Co, Melbourne. 2nd ed.
2. Billingham R.E., Brent L., Medawar P.B. Actively acquired tolerance of foreign cells. Nature 1953, 172:603-606.
3. Martin F., Chan A.C. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2009, 24:467-496.
4. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., et al. Projection of an immunological self shadow within the thymus by the Aire protein. Science 2002, 298:1395-1401.
5. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2003, 39:537-545.
6. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
7. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
8. Gregersen P.K., Behrens T.W. Genetics of autoimmune diseases-disorders of immune homeostasis. Nat Rev Genet 2006, 7:917-928.
9. Plenge R.M., Seielstad M., Padyukov L., Lee A.T., Remmers E.F., Ding B., et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 2007, 357:1199-1209.
10. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977-986.
11. Pritchard J.K., Cox N.J. The allelic architecture of human disease genes: common disease-common variant.. or not?. Hum Mol Genet 2002, 11:2417-2423.
12. Cohen J.C., Kiss R.S., Pertsemlidis A., Marcel Y.L., McPherson R., Hobbs H.H. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004, 305:869-872.
13. Lee-Kirsch M.A., Gong M., Chowdhury D., Senenko L., Engel K., Lee Y.A., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007, 39:1065-1067.
14. Kumar K.R., Li L., Yan M., Bhaskarabhatla M., Mobley A.B. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science 2006, 312:1665-1669.
15. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkani M., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004, 36:337-338.
16. Begovich A.B., Carlton V.E., Honigberg L.A., Schrodi S.J., Chokkalingam A.P., Alexander H.C., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75:330-337.
17. Smyth D., Cooper J.D., Collins J.E., Heward J.M., Franklyn J.A., Howson J.M., et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004, 53:3020-3023.
18. Menard L., Saadoun D., Isnardi I., Ng Y.S., Meyers F., Massad C., et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest 2011, 121:3635-3644.
19. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
20. Plenge R.M., Padyukov L., Remmers E.F., Purcell S., Lee A.T., Karlson E.W., et al. Replication of putative candidate-gene associations with rheumatoid arthritis in 4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005, 77:1044-1060.
21. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., Prince J., et al. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum 2004, 50:1770-1773.
22. Cornall R.J., Cyster J.G., Hibbs M.L., Dunn A.R., Opitoby K., Clark E.A., et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 1998, 8:497-508.
23. O'Keefe T.L., Williams G.T., Batista F.D., Neuberger M.S. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 1999, 189:1307-1313.
24. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000, 13:277-285.
25. Yu C.C., Mamchak A.A., DeFranco A.L. Signaling mutations and autoimmunity. Curr Dir Autoimmun 2003, 6:61-88.
26. McGaha T.L., Sorrentino B., Ravetch J.V. Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 2005, 307:590-593.
27. Floto R.A., Clatworthy M.R., Heilbronn K.R., Rosner D.R., MacAry P.A., Rankin A., et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med 2005, 11:1056-1058.
28. Kono H., Kyogoku C., Suzuki T., Tsuchiya N., Honda H., et al. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum Mol Genet 2005, 14:2881-2892.
29. Blank M.C., Stefanescu R.N., Masuda E., Marti F., King P.D., Redecha P.B., et al. Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005, 117:220-227.
30. Wang J.H., Avitahl N., Cariappa A., Friedrich C., Ikeda T., Renold A., et al. Aiolos regulates B cell activation and maturation to effector state. Immunity 1998, 9:543-554.
31. Cariappa A., Tang M., Parng C., Nebelitskiy E., Carroll M., Georgopoulos K., et al. The follicular versus marginal zone B lymphocyte cell fate decision is regulated by Aiolos, Btk, and CD21. Immunity 2001, 14:603-615.
32. Cariappa A., Pillai S. Antigen dependent B lymphocyte development. Curr. Opin. Immunol 2002, 14:241-249.
33. Pillai S., Cariappa A., Moran S.T. Positive selection and lineage commitment during peripheral B lymphocyte development. Immunol Rev 2004, 197:206-218.
34. Pillai S., Cariappa A., Moran S.T. Marginal Zone B Cells. Annu Rev Immunol 2005, 23:161-196.
35. O'Keefe T.L., Williams G.T., Davies S.L., Neuberger M.S. Hyperresponsive B cells in CD22-deficient mice. Science 1996, 274:798-801.
36. Otipoby K.L., Andersson K.B., Draves K.E., Klaus S.J., Farr A.G., Kerner J.D., et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 1996, 384:634-637.
37. Sato S., Miller A.S., Inaoki M., Bock C.B., Jansen P.J., Tang M.L., et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996, 5:551-562.
38. Nitschke L., Carsetti R., Ocker B., Kohler G., Lamers M.C. CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 1997, 7:133-143.
39. Samardzic T., Marinkovic D., Danzer C.P., Gerlach J., Nitschke L., Wirth T. Reduction of marginal zone B cells in CD22-deficient mice. Eur J Immunol 2002, 32:561-567.
40. Cariappa A., Mazo I.B., Chase C., Shi H.N., Liu H., Li Q., et al. Perisinusoidal B cells in the bone marrow participate in T-independent responses to blood-borne microbes. Immunity 2005, 23:397-407.
41. Stamenkovic I., Seed B. The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion. Nature 1990, 345:74-77.
42. Cyster J.G., Goodnow C.C. Tuning antigen receptor signaling by CD22: integrating cues from antigens and the microenvironment. Immunity 1997, 6:509-517.
43. Law C.L., Sidorenko S.P., Clark E.A. Regulation of lymphocyte activation by the cell-surface molecule CD22. Immunol Today 1994, 15:442-449.
44. Tedder T.F., Tuscano J., Sato S., Kehrl J.H. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997, 15:481-504.
45. Sgroi D., Varki A., Braesch-Andersen S., Stamenkovic I. CD22, a B cell-specific immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem 1993, 268:7011-7018.
46. Powell L.D., Sgroi D., Sjoberg E.R., Stamenkovic I., Varki A. Natural ligands of the B cell adhesion molecule CD22 beta carry N-linked oligosaccharides with alpha-2,6-linked sialic acids that are required for recognition. J Biol Chem 1993, 268:7019-7027.
47. Powell L.D., Varki A. The oligosaccharide binding specificities of CD22 beta, a sialic acid-specific lectin of B cells. J Biol Chem 1994, 269:10628-10636.
48. Powell L.D., Jain R.K., Matta K.L., Sabesan S., Varki A. Characterization of sialyloligosaccharide binding by recombinant soluble and native cell-associated CD22. Evidence for a minimal structural recognition motif and the potential importance of multisite binding. J Biol Chem 1995, 270:7523-7532.
49. Schulte R.J., Campbell M.A., Fischer W.H., Sefton B.M. Tyrosine phosphorylation of CD22 during B cell activation. Science 1992, 258:1001-1004.
50. Campbell M.A., Klinman N.R. Phosphotyrosine-dependent association between CD22 and protein tyrosine phosphatase 1C. Eur J Immunol 1995, 25:1573-1579.
51. Doody G.M., Justement L.B., Delibrias C.C., Matthews R.J., Lin J., Thomas M.L., et al. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 1995, 269:242-244.
52. Law C.L., Sidorenko S.P., Chandran K.A., Zhao Z., Shen S.H., Fischer E.H., et al. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma1 upon B cell activation. J Exp Med 1996, 183:547-560.
53. Smith K.G., Tarlinton D.M., Doody G.M., Hibbs M.L., Fearon D.T. Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med 1998, 187:807-811.
54. Han S., Collins B.E., Bengtson P., Paulson J.C. Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking. Nat Chem Biol 2005, 1:93-97.
55. Collins B.E., Smith B.A., Bengtson P., Paulson J.C. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat Immunol 2006, 7:199-206.
56. Jin L., McLean P.A., Neel B.G., Wortis H.H. Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling. J Exp Med 2002, 195:1199-1205.
57. Poe J.C., Fujimoto Y., Hasegawa M., Haas K.M., Miller A.S., Sanford I.G., et al. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat Immunol 2005, 5:1078-1087.
58. Cariappa A., Takematsu H., Liu H., Diaz S., Haider K., Boboila C., et al. B cell antigen receptor signal strength and peripheral B cell development are regulated by a 9-O-acetyl sialic acid esterase. J Exp Med 2009, 206:125-138.
59. Pillai S., Cariappa A., Pirnie S.P. Esterases and autoimmunity: the sialic acid acetylesterase pathway and the regulation of peripheral B cell tolerance. Trends Immunol 2009, 30:488-493.
60. Pillai S., Netravali I.A., Cariappa A., Mattoo H. Siglecs and immune regulation. Annu Rev Immunol 2012, 30:357-392.
61. Surolia I., Pirnie S.P., Chellappa V., Taylor K.N., Cariappa A., Moya J., et al. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 2010, 466:243-247.
62. Hirschfield G.M., Xie G., Lu E., Sun Y., Juran B.D., Chellappa V., et al. Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. Genes Immun 2012, 13:328-335.
63. Szymanski K., Skorka A., Szypowska A., Bednarczuk T., Ploski R. Functionally defective germline variant of sialic acid acetylesterase (Met89Val) is not associated with type 1 diabetes mellitus and Graves' disease in a Polish population. Tissue Antigens 2011, 78:214-216.
64. Hunt K.A., Smyth D.J., Balschun T., Ban M., Mistry V., Ahmad T., et al. Rare and functional SIAE variants are not associated with autoimmune disease risk in up to 66,924 individuals of European ancestry. Nat Genet 2012, 44:3-5.
65. Chellappa V., Taylor K.N., Pedrick K., Donado C., Netravali I.A., Haider K., et al. M89V sialic acid acetyl esterase (SIAE) and all other non-synonymous common variants of this gene are catalytically normal. PlOS One 2013, 8:e53453.
66. Zhou V.W., Goren A., Bernstein B.E. Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet 2011, 12:7-18.
67. Xiao C., Rajewsky K. MicroRNA control in the immune system: basic principles. Cell 2009, 136. 36-36.
68. Goodnow C.C. Multistep pathogenesis of autoimmune disease. Cell 2007, 130:25-35.
69. Honda K., Littman D.R. The microbiome in infectious disease and inflammation. Annu Rev. Immunol 2012, 30:759-795.
70. Ivanov, Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., et al. Induction of intenstinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
71. Wu H.-J., Ivanov, Darce J., Hattori K., Shima T., Umesaki Y., et al. Gut-residing segmented filamentous bacetria drive autoimmune arthritis via T helper 17 cells. Immunity 2010, 32:815-827.
72. Wen L., Ley R.E., Volchkov P.Y., Starnages P.B., Avanesyan L., Stonebrake A.C., et al. Innate immunity and intestinal microbiota in the development of type I diabetes. Natuere 2008, 455:1109-1113.
73. Atarshi K., Tanoue T., Shima T., Imaoka A., Kuwahara T., Momose Y., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2010, 331:337-341.
74. Larsen N., Vogensen F.K., van den Berg F.W., Nielsen D.S., Andreasen A.S., Pedersen B.K., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PloS one 2010, 5:e9085.
75. Giongo A., Gano K.A., Crabb D.B., Mukherjee N., Novelo L.L., Casella G., et al. Toward defining the autoimmune microbiome for type 1 diabetes. The ISME journal 2011, 5:82-91.
76. Morgan X.C., Tickle T.L., Sokol H., Gevers D., Devaney K.L., Ward D.V., et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome biology 2012, 13:R79.
77. Gao Z., Tseng C.H., Strober B.E., Pei Z., Blaser M.J. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PloS one 2008, 3:e2719.
78. Proal A.D., Albert P.J., Marshall T.G. The human microbiome and autoimmunity. Curr. Opin. Rheumatol 2013, 25:234-240.
79. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., Rose N.R., Gershwin M.E. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J. Autoimmun 2012, 39:272-284.
80. Gershwin M.E., Shoenfeld Y. Chella David: a lifetime contribution in translational immunology. J. Autoimmun 2011, 37:59-62.
81. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. J. Autoimmun 2012, 39:4-8.
82. Jamin C., Renaudineau Y., Pers J.O. Pierre Youinou: when intuition and determination meet autoimmunity. J. Autoimun 2012, 39:117-120.